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Fibroblast growth factor-2, but 
not the adipose tissue-derived 
stromal cells secretome, inhibits 
TGF-β1-induced differentiation 
of human cardiac fibroblasts into 
myofibroblasts
Tácia Tavares Aquinas Liguori1,2, Gabriel Romero Liguori1,2, Luiz Felipe Pinho Moreira  1 & 
Martin Conrad Harmsen  2
Transforming growth factor-β1 (TGF-β1) is a potent inducer of fibroblast to myofibroblast 
differentiation and contributes to the pro-fibrotic microenvironment during cardiac remodeling. 
Fibroblast growth factor-2 (FGF-2) is a growth factor secreted by adipose tissue-derived stromal cells 
(ASC) which can antagonize TGF-β1 signaling. We hypothesized that TGF-β1-induced cardiac fibroblast 
to myofibroblast differentiation is abrogated by FGF-2 and ASC conditioned medium (ASC-CMed). 
Our experiments demonstrated that TGF-β1 treatment-induced cardiac fibroblast differentiation into 
myofibroblasts, as evidenced by the formation of contractile stress fibers rich in αSMA. FGF-2 blocked 
the differentiation, as evidenced by the reduction in gene (TAGLN, p < 0.0001; ACTA2, p = 0.0056) and 
protein (αSMA, p = 0.0338) expression of mesenchymal markers and extracellular matrix components 
gene expression (COL1A1, p < 0.0001; COL3A1, p = 0.0029). ASC-CMed did not block myofibroblast 
differentiation. The treatment with FGF-2 increased matrix metalloproteinases gene expression (MMP1, 
p < 0.0001; MMP14, p = 0.0027) and decreased the expression of tissue inhibitor of metalloproteinase 
gene TIMP2 (p = 0.0023). ASC-CMed did not influence these genes. The proliferation of TGF-β1-induced 
human cardiac fibroblasts was restored by both FGF-2 (p = 0.0002) and ASC-CMed (p = 0.0121). The 
present study supports the anti-fibrotic effects of FGF-2 through the blockage of cardiac fibroblast 
differentiation into myofibroblasts. ASC-CMed, however, did not replicate the anti-fibrotic effects of 
FGF-2 in vitro.
Fibroblasts are the most abundant cell type in the heart and regulate the homeostasis of the extracellular matrix 
(ECM). The ECM provides the architecture of cardiac tissue, it supports the structural integrity and it regulates 
cellular communication and function. A major component of the ECM is collagen which is deposited primarily 
by cardiac fibroblasts1. Pathological stimuli, such as myocardial infarction, disrupt the cardiac tissue homeosta-
sis2 which predisposes the onset and progression of fibrosis3,4 by the activation and differentiation of fibroblasts 
into myofibroblasts1,5. Cardiac fibrosis features the production and deposition of excessive amounts of extra-
cellular matrix by cardiac myofibroblasts. Fibroblast activation and subsequent differentiation into myofibro-
blasts are primarily driven by transforming growth factor-β (TGF-β) and contributes to the pro-fibrotic cardiac 
microenvironment6–10.
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To date, no therapies exist that prevent or reverse fibrosis in vivo, yet it is possible to antagonize TGF-β sign-
aling with specific growth factors such as FGF-2. Fibroblast growth factor 2 (FGF-2) is relevant in wound heal-
ing processes in vivo11–13 and in vitro14–17 to stimulate proliferation of tissue cells, connective tissue fibroblasts 
and promote angiogenesis, while it suppresses apoptosis. Moreover, FGF-2 antagonizes TGF-β signaling and 
thus affects fibrosis, albeit in early stages18. In fibroblasts of various origins, FGF-2 suppressed the expression 
of TGFB119 and its protein16,20, that also suppressed the deposition of collagen21,22. All these studies suggest that 
FGF-2 is an attractive molecule to target in TGF-β regulated fibrotic disease.
Mesenchymal stromal cells (MSC), such as adipose tissue-derived stromal cells (ASC), as well as their con-
ditioned medium, have been shown to improve cardiac remodeling and thus to modulate cardiac fibrosis23–30. 
Because ASC release a series of anti-fibrotic factors, among which are FGF, IGF and HGF31–34, a possible mech-
anism underlying their anti-fibrotic effect could be to antagonize TGF-β signaling and thus the inhibition of the 
transformation of fibroblasts into myofibroblasts as well as the reduction of extracellular matrix production.
In a previous study, we demonstrated that TGF-β1-induced differentiation of dermal fibroblasts to myofi-
broblasts could be modulated by adipose tissue-derived stromal cells’ conditioned medium (ASC-CMed)35. 
Therefore, we hypothesized that cardiac fibroblast differentiation into myofibroblast could also be abrogated by 
ASC-CMed.
Results
Formation of F-actin stress fibers in differentiating NHCF-V is refractory to suppression by ASC-
CMed. After five days of pro-fibrotic stimulus, NHCF-V undergo myofibroblast differentiation, phalloidin 
detected F-actin and cells had an increase in αSMA expression (Fig. 1). Human cardiac fibroblast without TGF-β1 
stimuli had a mild phalloidin staining distributed all over the cytoplasm, on the other hand, the TGF-β1 stimu-
lated cells had the detection of phalloidin in the contractile fibers which had colocalization with the αSMA stain-
ing. FGF-2, but not ASC-CMed, could inhibit the phalloidin and αSMA in the contractile fibers. The expression 
of αSMA seems to be more evident in the TGF-β1 stimulated cells. As expected, TGF-β1 induced myofibroblast 
differentiation of cardiac fibroblasts which leads to the formation of smooth actin fibers at cytoskeletal level. Only 
FGF-2 inhibited the formation of these fibers.
FGF-2, but not ASC-CMed, inhibits the expression of mesenchymal markers in NHCF-V stimu-
lated with TGF-β1. The expression of mesenchymal genes TAGLN, encoding SM22α, and ACTA2, encoding 
αSMA, was increased TGF-β1 stimulated fibroblasts, irrespective of ASC-CMed (Fig. 2). FGF-2 suppressed the 
expression of TAGLN (One-way ANOVA, p < 0.0001; Sidak’s multiple comparison test, p < 0.0001) and ACTA2 
in cardiac fibroblasts stimulated with TGF-β1 (One-way ANOVA, p = 0.0007; Sidak’s multiple comparison 
test, p = 0.0056). The influence of ASC-CMed no more than tended to decrease TAGLN expression (One-way 
ANOVA, p < 0.0001; Sidak’s multiple comparison test, p = 0.0820) but not ACTA2 expression.
TGF-β1 upregulated the expression of αSMA in human cardiac fibroblasts which was blocked by FGF-2 
(Fig. 3) (One-way ANOVA, p = 0.0413; Sidak’s multiple comparison test, p = 0.0338). ASC-CMed did not alter 
the upregulation of αSMA by TGF-β1 (Fig. 3). Under these culture conditions, cardiac fibroblasts had a basal 
expression of SM22α which increased 1.4-fold after TGF-β1 stimulation. Thus, although FGF-2 inhibits the pro-
duction of αSMA, it could not reverse the expression of the already formed SM22α.
FGF2, but not ASC-CMed, modulates extracellular matrix production in NHCF-V stimulated 
with TGF-β1. The gene expression of collagens, as well as of matrix metalloproteinases (MMPs) - enzymes 
responsible for ECM degradation - and the tissue inhibitors of metalloproteinases (TIMPs), was analyzed. The 
stimulation with TGF-β1 upregulated the transcription of both COL1A1 and COL3A1, genes responsible for 
the protein synthesis of the alpha-1 chain of collagens I and III respectively (Fig. 4A,B). This increase was more 
pronounced for COL1A1. Treatment with FGF-2 in samples stimulated by TGF-β1 was responsible for a statis-
tically significant downregulation in COL1A1 (One-way ANOVA, p < 0.0001; Sidak’s multiple comparison test, 
p < 0.0001) and COL3A1 (One-way ANOVA, p = 0.0572; Sidak’s multiple comparison test, p = 0.0290), demon-
strating the strong inhibition of NHCF-V towards the myofibroblast phenotype.
Figure 1. Formation of F-actin stress fibers in differentiating NHCF-V is refractory to suppression by ASC-
CMed. Representative immunofluorescence micrographs of human cardiac fibroblasts (NHCF-V) under 
stimulation with TGF-β1 or co-stimulation with TGF-β1 and FGF-2, both in FBM and ASC-CMed, for 5 days. 
Upon TGF-β1 stimulation, cells developed transcellular αSMA-expressing stress fibers (arrows). ASC-CMed 
did not inhibit the development of stress fibers. Blue: DAPI; Green: phalloidin; Red: αSMA. Scale reference: 
100 μm.
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The gene expression of MMPs and TIMPs did not change irrespective of treatment, except for FGF-2 (Fig. 4C–
G). Expression of MMP1, encoding matrix metalloproteinase1 i.e. collagenase, was downregulated by TGF-β1. In 
contrast, FGF-2 upregulated MMP1 expression compared to control groups and TGF-β1 stimulation (One-way 
ANOVA, p < 0.0001; Sidak’s multiple comparison test, p < 0.0001). Treatment with ASC-CMed did not affect 
the TGF-ß-induced downregulation of MMP1 in NHCF-V. The expression of MMP2 gene was not regulated 
by TGF-ß, FGF or ASC-CMed (co)stimulation of NHCF-V. Although TGF-β1 did not affect the expression of 
MMP14, FGF-2 upregulated its expression (One-way ANOVA, p < 0.0001; Sidak’s multiple comparison test, 
p = 0.0027). Treatment with ASC-CMed tended to increase the expression of MMP14.
Figure 2. FGF-2, but not ASC-CMed, inhibits the gene expression of mesenchymal markers. (A) TAGLN, and 
(B) ACTA2, by RT-qPCR of NHCF-V after stimulation with TGFβ1 or co-stimulation with TGF-β1 and FGF-
2, both in FBM and ASC-CMed, for five days. Data were analyzed by One-way ANOVA with Sidak’s multiple 
comparison test for the groups FBM/TGF-β1 vs. FBM/TGF-β1/FGF-2 and FBM/TGF-β1 vs. ASC-CMed/TGF-
β1; p-values for the Sidak’s multiple comparison test are shown in the figure. Values represent mean ± SEM of 3 
independent experiments in duplicate.
Figure 3. FGF-2, but not ASC-CMed, inhibits the protein expression of mesenchymal markers. (A) SM22α, 
and (B) αSMA, by immunoblotting of NHCF-V after stimulation with TGFβ1 or co-stimulation with TGF-β1 
and FGF-2, both in FBM and ASC-CMed, for five days. Data were analyzed by One-way ANOVA with Sidak’s 
multiple comparison test for the groups FBM/TGF-β1 vs. FBM/TGF-β1/FGF-2 and FBM/TGF-β1 vs. ASC-
CMed/TGF-β1; p-values for the Sidak’s multiple comparison test are shown in the figure. Values represent 
mean ± SEM of 3 independent experiments.
www.nature.com/scientificreports/
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Expression of TIMPs genes TIMP1 and TIMP2 which are regulators of MMP activity had differential 
expression. Expression of TIMP1, remained unchanged irrespective of TGF-ß1 or ASC-CMed treatment. 
Expression of TIMP2 was decreased by FGF-2 (One-way ANOVA, p = 0.0005; Sidak’s multiple comparison test, 
p = 0.0023), while neither TGF-ß1 nor ASC-CMed affected its expression. Interestingly, TIMP2 is a co-factor of 
membrane-bound MMP14, which is e.g. responsible for activation of ECM-bound MMPs.
Immunofluorescence microscopy of intracellular collagen I demonstrated an increase in the protein content 
for all the groups stimulated with TGF-β1 (Fig. 5). FGF-2 could not decrease the intracellular collagen I at the 
microscopical level, so that virtually all the TGF-β1 stimulated cells and ASC-CMed/TGF-β1 expressed the pro-
tein in their cytoplasm. Both groups without TGF-β1 stimulation showed a very limited expression of collagen I.
FGF2 and ASC-CMed restore the TGF-ß1-inhibited proliferation of NHCF-V. NHCF-V prolifera-
tion was measured after five days of stimulation with TGF-β1. The pro-fibrotic stimulus led to a decrease in cell 
proliferation, as detected by Ki-67 staining. TGF-β1 suppressed the proliferation of human cardiac fibroblasts; 
control cells had 40.8% of proliferating cells compared to 22.3% in TGF-β1 stimulated cells (Fig. 6). Treatment 
with FGF-2, recovered the proliferation to 37.8% (One-way ANOVA, p < 0.0001; Sidak’s multiple comparison 
test, p = 0.0002) while the proliferation of fibroblasts cells stimulated with TGF-β1 was virtually rescued by 
Figure 4. FGF2, but not ASC-CMed, modulates the expression of extracellular matrix-related genes. (A) 
COL1A1, (B) COL3A1, (C) MMP1, (D) MMP2, (E) MMP14, (F) TIMP1, and (G) TIMP2 by RT-qPCR of 
NHCF-V after stimulation with TGF-β1 or co-stimulation with TGF-β1 and FGF-2, both in FBM and ASC-
CMed, for five days. Data were analyzed by One-way ANOVA with Sidak’s multiple comparison test for the 
groups FBM/TGF-β1 vs. FBM/TGF-β1/FGF-2 and FBM/TGF-β1 vs. ASC-CMed/TGF-β1; p-values for the 
Sidak’s multiple comparison test are shown in the figure. Values represent mean ± SEM of 3 independent 
experiments in duplicate.
www.nature.com/scientificreports/
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ASC-CMed (32.6%) (One-way ANOVA, p < 0.0001; Sidak’s multiple comparison test, p = 0.0121). Treatment of 
nonstimulated cardiac fibroblasts with ASC-CMed increased proliferation to 47.3%.
Wound healing is not affected by NHCF-V stimulation with TGF-β1. Wound healing was examined 
with a scratch assay and assessed after 24 hours. The percentage of gap closure did not differ among all groups 
(One-way ANOVA, p = 0.3716). Still, the treatment with FGF-2 or ASC-CMed tended to increase wound healing 
potential (Fig. 7).
Discussion
We demonstrated that FGF-2 - but not the secreted factors of adipose tissue-derived stromal cells – downmod-
ulate TGF-ß1-induced fibroblast into myofibroblast differentiation. Our results show that FGF-2 reduced differ-
entiation via the reduction of mesenchymal gene expression (TAGLN and ACTA2), and the reduction of αSMA 
expression subsequently. Concomitantly, we demonstrated that FGF-2 downregulated expression of collagens 
(COL1A1 and COL3A1), upregulate expression of matrix metalloproteinases (MMP1 and MMP14), and down-
regulated expression of inhibitor of metalloproteinase TIMP2. Finally, we showed that not only FGF-2 but also 
ASC-CMed restored the proliferation of TGF-β1-impaired fibroblasts.
TGF-β1 signaling is a pivotal mechanism of the activation of fibroblasts into myofibroblasts and, thus, fibro-
sis6–10. The ability of FGF-2 to antagonize TGF-β signaling, in turn, has been demonstrated in a series of stud-
ies17,36–39, each of these suggesting different mechanisms of interference on the TGF-β pathway. Among these 
suggested mechanisms are: the activation of ERK and JNK pathways17; the expression of let-7 miRNA, TGFβ 
Figure 5. Pro-collagen production in cardiac fibroblasts. Immunofluorescence analysis of expression of pro-
collagen in human cardiac fibroblasts undergoing myofibroblast differentiation for five days. Collagen I was 
upregulated upon TGF-β1 stimuli and neither ASC-CMed nor FGF-2 inhibited the process. Minor expression 
of collagen I was showed in cultured cells without TGF-β1 stimuli. Blue: DAPI; Yellow: collagen I. Scale 
reference: 200 μm.
Figure 6. FGF2 and ASC-CMed restore the TGF-ß1-inhibited proliferation of NHCF-V. Immunofluorescence 
proliferation analysis of human cardiac fibroblasts undergoing myofibroblast differentiation for five days. 
TGF-β1 stimuli downregulated the proliferation of cardiac fibroblasts. ASC-CMed and FGF-2 upregulated the 
proliferation. Blue: DAPI; Red: Ki-67. Scale reference: 200 μm. Data were analyzed by One-way ANOVA with 
Sidak’s multiple comparison test for the groups FBM/TGF-β1 vs. FBM/TGF-β1/FGF-2 and FBM/TGF-β1 vs. 
ASC-CMed/TGF-β1; p-values for the Sidak’s multiple comparison test are shown in the figure. Values represent 
mean ± SEM of 3 independent experiments in quadruplicate.
www.nature.com/scientificreports/
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receptor suppressor38,39; the expression of miRNA-20a, another repressor of the TGFβ receptor complex36; and 4 
the inhibition of the transcriptional regulator of muscle differentiation myf-540.
We hypothesized that, because ASC are known to secrete pro-regenerative growth factors such as FGF-2, 
treatment of human cardiac fibroblasts with ASC-CMed would abrogate TGF-β1-induced differentiation into 
myofibroblasts. Both gene and protein expression of mesenchymal and extracellular matrix-related markers 
showed that, differently than expected, ASC-CMed did not exert a noticeable effect on TGF-β1-induced myofi-
broblast activation. We did find, however, that ASC-CMed restored fibroblast proliferation impaired by TGF-β1 
stimulation. This finding might point to potential differences between the FGF-2 thresholds required for restoring 
proliferation and blocking differentiation. However, another possibility is that ASC produce other growth factors 
that also impact proliferation but are not involved in the differentiation process. In this regard, it has been pre-
viously shown that epidermal growth factor (EGF) from ASC was capable to enhance the proliferation of skin 
fibroblasts in vitro41.
To our knowledge, this is the first report to investigate the effects of conditioned medium from mesenchymal 
stromal cells - here ASC - in the TGF-β1-induced differentiation of cardiac fibroblasts into myofibroblasts. Several 
other studies, however, have investigated the effects of MSC secretome in the spontaneous differentiation of car-
diac fibroblasts42–46. Thus, although our findings oppose to many of the results described in these studies, there 
are important differences - which deserve attention - between published data and our current work (Table 1).
Three out of the five studies reported anti-fibrotic effects of MSC conditioned-medium on cardiac fibroblasts, 
including a reduction in expression of αSMA, collagens and TIMPs and increased MMPs expression and/or 
activity43,45,46. These studies were all performed with rat - not human - cardiac fibroblasts and none of these 
included a control group treated with Fibroblast Growth Medium (FGM), a medium capable to inhibit the spon-
taneous differentiation of fibroblasts, as we did. Thus, in this respect our results are not comparable to these 
studies for several reasons, the main being that the induction of cardiac fibroblast differentiation with TGF-β1 is 
a much more effective and powerful mechanism than the spontaneous differentiation, being consequently much 
more difficult to be blocked or reversed. Furthermore, both other studies which investigated the effects of MSC 
conditioned-medium on the spontaneous differentiation of cardiac fibroblasts reported either no differences42 
or even a trend towards the pro-fibrotic phenotype, with reduced MMP2 and MMP9 protein expression and 
activity and increased TIMP1 protein expression44. An important observation is that the concentration of FGF-2 
in the ASC-CMed could be too low to counteract TGF-β1 action, while it is enough to block spontaneous differ-
entiation. Previous studies demonstrated that the concentration of FGF-2 in ASC-CMed was less than 150 pg/
mL33,34, much lower than the FGF-2 concentration necessary to block the TGF-β1-induced differentiation in this 
study. Another point which deserves attention is the variety of factors secreted by ASC which could interfere 
with FGF-2 activity. Among the factors that might be involved in the FGF-2 blockage of TGF-β1 signaling are 
inflammatory factors, as INFα, TNFα, and IL-1β, which block the FGF receptor and, thus, do not allow FGF-2 
to inhibit TGF-β1 action39. In fact, studies demonstrated that ASC may release TNFα and IL-1β, besides many 
other interleukins33,47,48. These factors, together, could abrogate the effect of FGF-2 in the low doses it is found 
in ASC-CMed. Still, it is essential to highlight the fact that ASC also produce TGF-β, as demonstrated by several 
studies33,34,49,50. In this regard, Rehman et al. showed that ASC produce around ten times more TGF-β than FGF-
234. The conjoint action of all these factors, which are contained in the ASC secretome, could explain, in part, the 
insufficiency of ASC-CMed to block the fibrotic stimule.
Still, in our view, the partial recapitulation in vitro of the fibroblast-related component of cardiac fibrosis, 
with the use of primary human cardiac fibroblast cultured in FGM and induced with TGF-β1 is a suitable in 
vitro model of the natural conditions in the fibrotic heart. Thus, considering the controversial findings between 
the studies using the spontaneous differentiation in addition to the results of the present study, we consider 
that in TGF-β-driven cardiac fibrosis ASC-CMed may not suffice as a sole therapeutic modality to block or 
reverse ongoing fibrosis. FGF-2, however, corroborating with the findings of two previous studies21,22, did block 
TGF-β1-induced pro-fibrotic conversion of cardiac human fibroblasts.
The present study supports the anti-fibrotic effects of FGF-2 through the blockage of NHCF-V differenti-
ation into myofibroblasts, as demonstrated by the modulation of gene and/or protein expression in a series of 
Figure 7. Wound healing is not affected by NHCF-V stimulation with TGF-β1. Wound healing assay (24 h) in 
NHCF-V under stimulation with TGF-β1 or co-stimulation with TGF-β1 and FGF-2, both in FBM and ASC-
CMed. Original magnification: 4x. Values represent mean ± SEM of 3 independent experiments in triplicate.
www.nature.com/scientificreports/
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mesenchymal and extracellular matrix-related markers. ASC-CMed, however, could not demonstrate the same 
effects found with FGF-2.
Methods
Experimental groups. Ventricular normal human cardiac fibroblasts (NHCF-V) were allocated into 5 
groups with different induction/FGF-2/ASC-CMed combinations, as described in Table 2.
Cell sources, cell culture, and conditioned medium. Ventricular normal human cardiac fibroblasts 
were purchased from Lonza (NHCF-V; #CC-2904, Lonza, Basel, Switzerland) and cultured with Fibroblast 
Growth Medium-3 with 10% of fetal bovine serum (FBS) (FGM3; #CC-4526, Lonza, Basel, Switzerland) added 
with 500 ng/mL Amphotericin B (#15290018, Gibco Invitrogen, Carlsbad, USA) at 37 °C in a humidified incu-
bator with 5% CO2. The medium was refreshed every 3 days. Cells were passed at a ratio of 1:3 after reaching 
confluency. NHCF-V were used between passages 3–5.
At day 0 of the experiment, NHCF-V were seeded at a 10,000 cells/cm2 density. After 24 hours, NHCF-V 
were allocated into the 5 distinct groups and cultured for 5 days. Fibroblast growth factor 2 (FGF-2; #100-18C, 
PeproTech, Inc., Rocky Hill, N.J.) and human transforming growth factor-beta 1 (TGF-β1; #100-21, PeproTech, 
New Jersey, USA) were used at a concentration of 10 ng/mL and 5 ng/mL, respectively, in all experiments.
Human ASC were isolated as described previously51. Briefly, human abdominal fat was obtained by lipo-
suction, washed with phosphate-buffered saline (PBS) and digested enzymatically with 0.1% collagenase A 
(#11088793001, Roche Diagnostic, Mannheim, Germany) in PBS with 1% bovine serum albumin (BSA; #A9647, 




medium MSC conditioned medium
Differentiation 
induction Findings
Ohnishi et al.42 primary SD rat atrial fibroblast
αMEM 
(10% FBS)
αMEM (10% FBS)-based CM 
from Lewis rat BM-MSC cultured 
for 48 h







MEM (10% FBS)-based CM from 
Lewis rat BM-MSC cultured for 
24 h*
spontaneous
↓ αSMA protein expression
↓ collagens I and III deposition
↑ MMP2 and MMP9 activity







transwell co-culture with SD rat 
BM-MSC in DMEM (10% FBS) spontaneous
↓ MMP2 protein expression = MMP9 protein expression
↓ MMP2 activity = MMP9 activity







DMEM (10% FBS)-based CM from 




↓ COL1A1 and COL3A1 gene expression
↑ MMP2 and MMP9 gene expression







gap mode co-culture with human 
ASC in MSC growth medium(NS) spontaneous ↓ αSMA expression







DMEM (10% FBS)-based CM 
from human ASC cultured for 
24 h, concentrated 30X, and 
resuspended in FGM (2% FBS)
5 ng/mL of 
TGF-β1
= TAGLN and ACTA2 gene expression  
= SM22α and αSMA protein expression  
= COL1A1 and COL3A1 gene expression  
= MMP1, MMP2 and MMP14 gene expression  
= TIMP1 and TIMP2 gene expression ↑ proliferation  
= wound healing potential
Table 1. Overview of the studies investigating the effects of MSC conditioned medium in cardiac fibroblasts. 
MSC: mesenchymal stromal cells; SD: Sprague-Dawley; αMEM: α-Minimal Essential Medium; FBS: fetal 
bovine serum; CM: conditioned medium; BM-MSC: bone marrow mesenchymal stromal cells; DMEM: 
Dulbecco’s Modified Eagle Media; MEM: Minimal Essential Medium; ASC: adipose tissue-derived stromal 
cells; FGM: Fibroblast Growth Medium; NS: not specified. *Used the same medium, not conditioned, as 
control. **Fibroblasts pre-conditioned under hypoxia. ***Concentration ratio and resuspension method (if 
any) not described.
Group Description
FBM NHCF-V culture with FGM2, without added factors.
FBM/TGF-β1 NHCF-V culture with FGM2 added with TGF-β1.
FBM/TGF-β1/FGF-2 NHCF-V culture with FGM2 added with TGF-β1 and FGF-2
ASC-CMed NHCF-V culture with ASC conditioned media, without added factors.
ASC-CMed/TGF-β1 NHCF-V culture with ASC conditioned media added with TGF-β1
Table 2. Experimental Groups. FBM: Fibroblast media; FGM2: Fibroblast growth media with 2% of fetal 
bovine serum; NHCF-V: Ventricular normal human cardiac fibroblasts; FGF-2: Fibroblast growth factor 2; 
TGF-β1: transforming growth factor-beta 1; ASC-CMed: Conditioned Medium derived from Adipose tissue-
derived stromal cells.
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was mixed with 1% PBS/BSA, filtered, centrifuged and the cell pellet was resuspended in Dulbecco’s Modified 
Eagle’s Medium (DMEM; #12-604F, Lonza, Basel, Switzerland) with 10% fetal bovine serum (FBS; #F0804, 
Sigma-Aldrich, Missouri, United States), 1% penicillin/streptomycin (#15140122, Gibco Invitrogen, Carlsbad, 
USA) and 1% L-glutamine (#17-605E, Lonza Biowhittaker, Verviers, Belgium). Cells were cultured at 37 °C in a 
humidified incubator with 5% CO2. The medium was refreshed every 2 days. Cells were passed at a ratio of 1:3 
after reached confluency.
ASC conditioned medium (ASC-CMed) was obtained from confluent cultures of ASC between passages 3 
and 6 from at least 3 different donors. For ASC-CMed, cells were cultured in DMEM without serum. Cells were 
kept at 37 °C with a minimum relative humidity of 95% and an atmosphere of 5% CO2 in the air. The conditioned 
medium was harvested after 24 hours, passed through a 0.22 µm filter and stored t −20 °C until use. Before the 
experiment, the conditioned medium was concentrated 30 times using Amicon® Ultra 15 mL filters (UFC900324, 
Merck, Darmstadt, Germany) and resuspended to the initial volume using Fibroblast Growth Medium-2 (FGM2; 
#CC-3132, Lonza, Basel, Switzerland).
Immunofluorescence, gene expression, and immunoblotting. Immunofluorescence. NHCF-V 
were cultured in 48 well tissue culture plates. After 5 and 21 days of induction, cells were fixed at room tem-
perature with 2% paraformaldehyde (PFA) for 30 minutes. Cells were permeabilized with 1% Triton-X100 in 
PBS for 15 minutes at room temperature and blocked with 5% donkey serum in PBS and 1% BSA for another 
15 minutes at room temperature. Subsequently, cells were incubated with primary antibodies diluted in 5% 
donkey serum in PBS for 2 hours at room temperature. The following primary antibodies were used: mouse 
anti-αSMA (1:400; #ab5694, Abcam, Cambridge, UK), rabbit anti-collagen I (1:200, #ab34710, Abcam, 
Cambridge, UK), rabbit anti-collagen III (1:200, #ab34710, Abcam, Cambridge, UK) and rabbit anti Ki-67 (1:400; 
#ab15580, Abcam, Cambridge, UK). Controls were incubated with 5% donkey serum in PBS. Next, cells were 
washed with 0.05% Tween-20 in PBS and incubated with secondary antibodies in 5% donkey serum in PBS with 
4′,6-diamidino-2-phenylindole (DAPI; 1:5000; #D9542-5MG, Sigma-Aldrich, Missouri, United States) and Alexa 
Fluor® 488 phalloidin (1:400; #A12379, Life Technologies, Carlsbad, United States) for 1 hour at room temper-
ature. The following secondary antibodies were used: donkey anti-rabbit IgG (H + L) Alexa Fluor® 594 (1:400; 
#A-21207, Life Technologies, Carlsbad, United States) and donkey anti-mouse IgG (H + L) Alexa Fluor® 647 
(1:400; #A-31571, Life Technologies, Carlsbad, United States). Finally, cells were washed 3 times with PBS and 
the plates were imaged with Evos FL System (Thermo Fisher Scientific, Waltham, United States) using Texas Red 
(TXR), Cy5, DAPI and Green Fluorescent Protein (GFP) channels with 20x magnification.
Gene expression analysis. NHCF-V were cultured in 25 cm2 flasks. After 5 days of induction, RNA isolation 
was performed using TRIzol reagent (#15596018, Invitrogen Corp, Carlsbad, United States) according to the 
manufacturer’s protocol. RNA concentration and purity were determined using NanoDrop technology (Thermo 
Scientific, Hemel Hempstead, United Kingdom). Between 300 ng and 500 ng of total RNA was used for cDNA 
synthesis, which was performed using RevertAidTM First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, 
Waltham, United States) according to the manufacturer’s protocol. The cDNA-equivalent of 5 ng total RNA 
was used per single qPCR reaction. PCR was performed using SYBR Green (Bio-Rad, Hercules, United States) 
with the ViiA7 Real-Time PCR system (Applied Biosystems, Foster City, United States). Each analysis was done 
in duplicate for each one of the independent experiments. The primers used are listed in the Supplementary 
Table S1. Data were analyzed using ViiA7 software (Applied Biosystems, Foster City, United States) and normal-
ized with the ∆Ct method, using the geometrical mean of 18S ribosomal RNA (18S RNA) cycle threshold (CT) 
values. The fold-change in gene expression versus the no treatment control group (ECM) was calculated using 
the ∆∆CT method.
Immunoblotting analysis. NHCF-V were cultured in 25 cm2 flasks. After 5 days of induction, cells were rinsed 
with cold PBS and lysed in 100 µL of cold lysis buffer (RIPA; #89900, Thermo Fisher Scientific, Waltham, United 
States) containing 1% protease inhibitor cocktail (PIC; #P8340, Sigma Aldrich, St. Louis, United States) and 1% 
Halt™ phosphatase inhibitor cocktail (#78420, Thermo Fisher Scientific, Waltham, United States). The lysed cells 
were collected in 2 mL microcentrifuge tubes and the contents homogenized by sonication at 30 W for 30 seconds 
and centrifuged at 7,500 g at 4 °C for 5 minutes. The supernatant was collected for the protein concentration 
determination using the Bio-Rad DC protein assay (#5000112; Bio-Rad, Hercules, United States) according to 
the manufacturer’s protocol. Gels (12%) were loaded with 4–10 μg of protein. After electrophoresis, gels were 
blotted onto nitrocellulose membranes (#170-4270; Bio-Rad, Hercules, United States). Blots were blocked with 
Odyssey® Blocking Buffer (#927-40000, LI-COR, Lincoln, USA) in a dilution of 1:1 with PBS overnight at 4 °C. 
Afterward, blots were incubated with the primary antibodies overnight. The following primary antibodies were 
used: rabbit anti-SM22α (1:1000; #ab14106, Abcam, Cambridge, UK), mouse anti-αSMA (1:1000; #ab5694, 
Abcam, Cambridge, UK) and rabbit anti-GAPDH (1:1000; #ab9485, Abcam, Cambridge, UK). Then, the mem-
branes were washed during 30 minutes with Tris-buffered saline with 0.1% Tween-20 (TBST) and incubated for 
1 hour with the Odyssey® secondary antibodies goat anti-rabbit IRDye 680LT (1:10000; #926-68021, LI-COR, 
Lincoln, USA) and goat anti-mouse IRDye 800CW (1:10,000; #926-32210, LI-COR, Lincoln, USA). Non-bound 
secondary antibodies were removed by washing with TBST for 30 minutes. Then, blots were washed for 5 minutes 
with Tris-buffered saline (TBS) and scanned with Odyssey® Infrared Imaging System (LI-COR, Lincoln, USA).
Wound healing assay. NHCF-V were seeded in 48-well tissue culture plates at a density of 15,000 cells/
cm2 and cultured in FGM3, 37 °C, and 5% CO2 until 70% confluence was reached. Them, cells were divided into 
5 groups and stimulated for 5 days, as prescribed previously. After this period, the confluent monolayers were 
scored with a 10 µl sterile pipette tip to leave a scratch of approximately 0.4–0.5 mm in width. Culture medium 
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was, then, immediately removed and cells were carefully washed with PBS - to remove any dislodged cells - and 
the medium was replaced with fresh FGM2. Pictures were taken immediately after the scratch and, again, after 
24 hours. The percentage of wound reduction was evaluated in ImageJ.
Statistical analysis. All data were obtained from at least three independent experiments, performed in 
duplicate or triplicate. Data are presented as mean ± standard error of the mean (SEM). Graphs and statisti-
cal analysis were done using GraphPad Prism (Version 6.01; GraphPad Software, Inc., La Jolla, United States). 
Differences among multiple groups were analyzed by One-way ANOVA with Sidak’s multiple comparison test 
for the following groups: FGM2/TGF-β1 vs. FGM2/TGF-β1/FGF-2 and FGM2/TGF-β1 vs. ASC-CMed/TGF-β1.
Data Availability Statement
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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